IGI reports phase 1 results of ISB 2001 trispecific antibody in relapsed or refractory multiple myeloma Read more
Ichnos Glenmark Innovation presents first clinical data from phase 1 study of Trispecific TREAT Antibody, ISB 2001 Read more